Qassim, Saudi Arabia — The Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO) has opened a cutting-edge oncology drug plant in Qassim. Built for SAR 272 million, the new facility spans 2,800 square meters. It marks a major step in Saudi Arabia’s push to expand local pharmaceutical manufacturing. The SPIMACO oncology drug plant Qassim will focus on producing high-potency cancer medications.

Boosting Saudi Pharmaceutical Manufacturing with High-Precision Capacity

The plant is scheduled to begin commercial production in August 2025. It has a capacity of over 275 million treatment units per year and meets strict global quality and safety standards. This launch puts SPIMACO at the forefront of Saudi drug production. It supports national efforts to reduce dependence on imported medicines.

SPIMACO confirmed that all regulatory, technical, and operational approvals are complete. The facility features advanced automation and strong safety measures, protecting workers and the environment while ensuring uninterrupted operations.

Strategic Partnerships and Vision 2030 Alignment

This project goes beyond industrial growth—it’s a strategic move. On November 17, 2025, SPIMACO signed an agreement with AstraZeneca to localize the production of oncology and high-potency medicines. The partnership reflects Saudi Arabia’s growing reputation as a regional base for global pharmaceutical firms.

SPIMACO operates in 16 countries and offers a broad range of medical products. The new Qassim facility strengthens its presence in the domestic and regional markets. More importantly, local production advances public health and economic resilience.

By investing in advanced pharmaceutical manufacturing, SPIMACO is helping Saudi Arabia achieve its Vision 2030 goals, which include innovation in healthcare, industrial development, and greater national self-reliance.

 

 

THE SAUDI STANDARD’S VIEW: Oncology Drug Plant Anchors Saudi Pharma Sovereignty

Launching the SPIMACO oncology drug plant Qassim marks a major step in Saudi Arabia’s path toward pharmaceutical independence. The SAR 272 million facility directly supports Vision 2030 and shows how local innovation can meet national healthcare needs.

  • The plant fills critical supply gaps by focusing on high-potency and cancer treatments. It enables Saudi Arabia to produce essential medicines while global demand for these therapies continues to rise.
  • With a more than 275 million treatment units capacity and compliance with international standards, the facility reflects high-quality engineering and regulatory strength. It highlights the growth of Saudi expertise in drug manufacturing.
  • The recent partnership with AstraZeneca shows Saudi Arabia’s appeal to global pharma leaders. This collaboration brings technology and trust while creating local value.
  • Choosing Qassim for this project supports national goals to balance economic growth across regions. It also helps improve healthcare access and creates skilled jobs in a high-impact sector.

In summary, the new oncology facility strengthens Saudi Arabia’s ability to manage health challenges. It also highlights the importance of building domestic capacity in vital industries. SPIMACO demonstrates how targeted investments can secure public health and long-term economic strength through this plant.

 

Related Reading